http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 01 Jun 2026 07:30:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Cabaletta+Bio%2C+Inc.++++++++++++++++++/26579236.html si-local-file:///var/storage/secattach/20260601/26579236.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Cabaletta+Bio%2C+Inc.++++++++++++++++++/26579236.html Mon, 01 Jun 2026 07:30:00 -0400 CABA O.41847823 http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Cabaletta+Bio%2C+Inc.++++++++++++++++++/26579236.html si-local-file:///var/storage/secattach/20260601/26579236.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Cabaletta+Bio%2C+Inc.++++++++++++++++++/26579236.html Mon, 01 Jun 2026 07:30:00 -0400 CABA O.41847823 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Cabaletta+Bio%2C+Inc.++++++++++++++++++++Filed+by%3A+Cormorant+Asset+Management%2C+LP/26503239.html si-local-file:///var/storage/secattach/20260515/26503239.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Cabaletta+Bio%2C+Inc.++++++++++++++++++++Filed+by%3A+Cormorant+Asset+Management%2C+LP/26503239.html Fri, 15 May 2026 13:21:00 -0400 CABA O.41847823 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Cabaletta+Bio%2C+Inc.++++++++++++++++++++Filed+by%3A+Cormorant+Asset+Management%2C+LP/26503239.html si-local-file:///var/storage/secattach/20260515/26503239.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Cabaletta+Bio%2C+Inc.++++++++++++++++++++Filed+by%3A+Cormorant+Asset+Management%2C+LP/26503239.html Fri, 15 May 2026 13:21:00 -0400 CABA O.41847823 http://www.streetinsider.com/Analyst+PT+Change/Cabaletta+Bio+%28CABA%29+PT+Raised+to+%244+at+Wells+Fargo/26498609.html Wells Fargo analyst Derek Archila raised the price target on Cabaletta Bio (NASDAQ: CABA) to $4.00 (from $2.00) while maintaining a Equal Weight rating. http://www.streetinsider.com/Analyst+PT+Change/Cabaletta+Bio+%28CABA%29+PT+Raised+to+%244+at+Wells+Fargo/26498609.html Fri, 15 May 2026 06:28:48 -0400 CABA http://www.streetinsider.com/Earnings/Cabaletta+Bio%2C+Inc.+%28CABA%29+Reports+In-Line+Q1+EPS/26490011.html <p>Cabaletta Bio, Inc. (NASDAQ: CABA) reported Q1 EPS of ($0.39), in-line with the analyst estimate of ($0.39).</p><p>For earnings history and earnings-related data on Cabaletta Bio, Inc. (CABA) <a href="http://www.streetinsider.com/ec_earnings.php?q=CABA">click here</a>.</p> http://www.streetinsider.com/Earnings/Cabaletta+Bio%2C+Inc.+%28CABA%29+Reports+In-Line+Q1+EPS/26490011.html Thu, 14 May 2026 07:35:38 -0400 CABA http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Cabaletta+Bio%2C+Inc.+++++++For%3A+Mar+31/26489795.html si-local-file:///var/storage/secattach/20260514/26489795.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Cabaletta+Bio%2C+Inc.+++++++For%3A+Mar+31/26489795.html Thu, 14 May 2026 07:09:00 -0400 CABA O.41847823 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Cabaletta+Bio%2C+Inc.+++++++For%3A+Mar+31/26489795.html si-local-file:///var/storage/secattach/20260514/26489795.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Cabaletta+Bio%2C+Inc.+++++++For%3A+Mar+31/26489795.html Thu, 14 May 2026 07:09:00 -0400 CABA O.41847823 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cabaletta+Bio%2C+Inc.+++++++For%3A+May+14/26489785.html si-local-file:///var/storage/secattach/20260514/26489785.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cabaletta+Bio%2C+Inc.+++++++For%3A+May+14/26489785.html Thu, 14 May 2026 07:07:00 -0400 CABA O.41847823 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cabaletta+Bio%2C+Inc.+++++++For%3A+May+14/26489785.html si-local-file:///var/storage/secattach/20260514/26489785.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cabaletta+Bio%2C+Inc.+++++++For%3A+May+14/26489785.html Thu, 14 May 2026 07:07:00 -0400 CABA O.41847823 http://www.streetinsider.com/Press+Releases/Cabaletta+Bio+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26489765.html <p align="center"><em>Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV</em><em>®</em><em> study presented today at ASGCT 2026 Annual Meeting along with initial rese-cel translational data using Cellares’ industrialized, automated manufacturing</em></p> <p align="center"><em>PC-free rese-cel initial data from the lowest dose RESET-SLE™ cohort expected in 1H26</em></p> <p align="center"><em>Pivotal RESET-Myositis</em><em>®</em><em> cohort with outpatient dosing option progressing to support first planned BLA submission for rese-cel next year</em></p> <p align="center"><em>Second pivotal indication for advancement to be announced after presentation of complete Phase 1/2 lupus and scleroderma data during June 2026 EULAR Congress</em></p> <p>PHILADELPHIA, http://www.streetinsider.com/Press+Releases/Cabaletta+Bio+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26489765.html Thu, 14 May 2026 07:05:00 -0400 A.50200932 A.50214086 A.60012014 CABA O.05000176 O.29757805 O.41847823 O.42045967 http://www.streetinsider.com/Press+Releases/Cabaletta+Bio+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26489765.html <p align="center"><em>Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV</em><em>®</em><em> study presented today at ASGCT 2026 Annual Meeting along with initial rese-cel translational data using Cellares’ industrialized, automated manufacturing</em></p> <p align="center"><em>PC-free rese-cel initial data from the lowest dose RESET-SLE™ cohort expected in 1H26</em></p> <p align="center"><em>Pivotal RESET-Myositis</em><em>®</em><em> cohort with outpatient dosing option progressing to support first planned BLA submission for rese-cel next year</em></p> <p align="center"><em>Second pivotal indication for advancement to be announced after presentation of complete Phase 1/2 lupus and scleroderma data during June 2026 EULAR Congress</em></p> <p>PHILADELPHIA, http://www.streetinsider.com/Press+Releases/Cabaletta+Bio+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26489765.html Thu, 14 May 2026 07:05:00 -0400 A.50200932 A.50214086 A.60012014 CABA O.05000176 O.29757805 O.41847823 O.42045967 http://www.streetinsider.com/Press+Releases/Cabaletta+Bio+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26489765.html <p align="center"><em>Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV</em><em>®</em><em> study presented today at ASGCT 2026 Annual Meeting along with initial rese-cel translational data using Cellares’ industrialized, automated manufacturing</em></p> <p align="center"><em>PC-free rese-cel initial data from the lowest dose RESET-SLE™ cohort expected in 1H26</em></p> <p align="center"><em>Pivotal RESET-Myositis</em><em>®</em><em> cohort with outpatient dosing option progressing to support first planned BLA submission for rese-cel next year</em></p> <p align="center"><em>Second pivotal indication for advancement to be announced after presentation of complete Phase 1/2 lupus and scleroderma data during June 2026 EULAR Congress</em></p> <p>PHILADELPHIA, http://www.streetinsider.com/Press+Releases/Cabaletta+Bio+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26489765.html Thu, 14 May 2026 07:05:00 -0400 A.50200932 A.50214086 A.60012014 CABA O.05000176 O.29757805 O.41847823 O.42045967 http://www.streetinsider.com/Press+Releases/Cabaletta+Bio+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26489765.html <p align="center"><em>Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV</em><em>®</em><em> study presented today at ASGCT 2026 Annual Meeting along with initial rese-cel translational data using Cellares’ industrialized, automated manufacturing</em></p> <p align="center"><em>PC-free rese-cel initial data from the lowest dose RESET-SLE™ cohort expected in 1H26</em></p> <p align="center"><em>Pivotal RESET-Myositis</em><em>®</em><em> cohort with outpatient dosing option progressing to support first planned BLA submission for rese-cel next year</em></p> <p align="center"><em>Second pivotal indication for advancement to be announced after presentation of complete Phase 1/2 lupus and scleroderma data during June 2026 EULAR Congress</em></p> <p>PHILADELPHIA, http://www.streetinsider.com/Press+Releases/Cabaletta+Bio+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26489765.html Thu, 14 May 2026 07:05:00 -0400 A.50200932 A.50214086 A.60012014 CABA O.05000176 O.29757805 O.41847823 O.42045967 http://www.streetinsider.com/Press+Releases/Cabaletta+Bio+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26489765.html <p align="center"><em>Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV</em><em>®</em><em> study presented today at ASGCT 2026 Annual Meeting along with initial rese-cel translational data using Cellares’ industrialized, automated manufacturing</em></p> <p align="center"><em>PC-free rese-cel initial data from the lowest dose RESET-SLE™ cohort expected in 1H26</em></p> <p align="center"><em>Pivotal RESET-Myositis</em><em>®</em><em> cohort with outpatient dosing option progressing to support first planned BLA submission for rese-cel next year</em></p> <p align="center"><em>Second pivotal indication for advancement to be announced after presentation of complete Phase 1/2 lupus and scleroderma data during June 2026 EULAR Congress</em></p> <p>PHILADELPHIA, http://www.streetinsider.com/Press+Releases/Cabaletta+Bio+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26489765.html Thu, 14 May 2026 07:05:00 -0400 A.50200932 A.50214086 A.60012014 CABA O.05000176 O.29757805 O.41847823 O.42045967 http://www.streetinsider.com/Press+Releases/Cabaletta+Bio+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26489765.html <p align="center"><em>Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV</em><em>®</em><em> study presented today at ASGCT 2026 Annual Meeting along with initial rese-cel translational data using Cellares’ industrialized, automated manufacturing</em></p> <p align="center"><em>PC-free rese-cel initial data from the lowest dose RESET-SLE™ cohort expected in 1H26</em></p> <p align="center"><em>Pivotal RESET-Myositis</em><em>®</em><em> cohort with outpatient dosing option progressing to support first planned BLA submission for rese-cel next year</em></p> <p align="center"><em>Second pivotal indication for advancement to be announced after presentation of complete Phase 1/2 lupus and scleroderma data during June 2026 EULAR Congress</em></p> <p>PHILADELPHIA, http://www.streetinsider.com/Press+Releases/Cabaletta+Bio+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26489765.html Thu, 14 May 2026 07:05:00 -0400 A.50200932 A.50214086 A.60012014 CABA O.05000176 O.29757805 O.41847823 O.42045967 http://www.streetinsider.com/Press+Releases/Cabaletta+Bio+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26489765.html <p align="center"><em>Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV</em><em>®</em><em> study presented today at ASGCT 2026 Annual Meeting along with initial rese-cel translational data using Cellares’ industrialized, automated manufacturing</em></p> <p align="center"><em>PC-free rese-cel initial data from the lowest dose RESET-SLE™ cohort expected in 1H26</em></p> <p align="center"><em>Pivotal RESET-Myositis</em><em>®</em><em> cohort with outpatient dosing option progressing to support first planned BLA submission for rese-cel next year</em></p> <p align="center"><em>Second pivotal indication for advancement to be announced after presentation of complete Phase 1/2 lupus and scleroderma data during June 2026 EULAR Congress</em></p> <p>PHILADELPHIA, http://www.streetinsider.com/Press+Releases/Cabaletta+Bio+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26489765.html Thu, 14 May 2026 07:05:00 -0400 A.50200932 A.50214086 A.60012014 CABA O.05000176 O.29757805 O.41847823 O.42045967 http://www.streetinsider.com/Press+Releases/Cabaletta+Bio+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26489765.html <p align="center"><em>Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV</em><em>®</em><em> study presented today at ASGCT 2026 Annual Meeting along with initial rese-cel translational data using Cellares’ industrialized, automated manufacturing</em></p> <p align="center"><em>PC-free rese-cel initial data from the lowest dose RESET-SLE™ cohort expected in 1H26</em></p> <p align="center"><em>Pivotal RESET-Myositis</em><em>®</em><em> cohort with outpatient dosing option progressing to support first planned BLA submission for rese-cel next year</em></p> <p align="center"><em>Second pivotal indication for advancement to be announced after presentation of complete Phase 1/2 lupus and scleroderma data during June 2026 EULAR Congress</em></p> <p>PHILADELPHIA, http://www.streetinsider.com/Press+Releases/Cabaletta+Bio+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26489765.html Thu, 14 May 2026 07:05:00 -0400 A.50200932 A.50214086 A.60012014 CABA O.05000176 O.29757805 O.41847823 O.42045967 http://www.streetinsider.com/Globe+Newswire/Cabaletta+Bio+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26489765.html <p align="center"><em>Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV</em><em>®</em><em> study presented today at ASGCT 2026 Annual Meeting along with initial rese-cel translational data using Cellares’ industrialized, automated manufacturing</em></p> <p align="center"><em>PC-free rese-cel initial data from the lowest dose RESET-SLE™ cohort expected in 1H26</em></p> <p align="center"><em>Pivotal RESET-Myositis</em><em>®</em><em> cohort with outpatient dosing option progressing to support first planned BLA submission for rese-cel next year</em></p> <p align="center"><em>Second pivotal indication for advancement to be announced after presentation of complete Phase 1/2 lupus and scleroderma data during June 2026 EULAR Congress</em></p> <p>PHILADELPHIA, http://www.streetinsider.com/Globe+Newswire/Cabaletta+Bio+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26489765.html Thu, 14 May 2026 07:05:00 -0400 A.50200932 A.50214086 A.60012014 CABA O.05000176 O.29757805 O.41847823 O.42045967 http://www.streetinsider.com/Globe+Newswire/Cabaletta+Bio+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26489765.html <p align="center"><em>Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV</em><em>®</em><em> study presented today at ASGCT 2026 Annual Meeting along with initial rese-cel translational data using Cellares’ industrialized, automated manufacturing</em></p> <p align="center"><em>PC-free rese-cel initial data from the lowest dose RESET-SLE™ cohort expected in 1H26</em></p> <p align="center"><em>Pivotal RESET-Myositis</em><em>®</em><em> cohort with outpatient dosing option progressing to support first planned BLA submission for rese-cel next year</em></p> <p align="center"><em>Second pivotal indication for advancement to be announced after presentation of complete Phase 1/2 lupus and scleroderma data during June 2026 EULAR Congress</em></p> <p>PHILADELPHIA, http://www.streetinsider.com/Globe+Newswire/Cabaletta+Bio+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26489765.html Thu, 14 May 2026 07:05:00 -0400 A.50200932 A.50214086 A.60012014 CABA O.05000176 O.29757805 O.41847823 O.42045967 http://www.streetinsider.com/Globe+Newswire/Cabaletta+Bio+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26489765.html <p align="center"><em>Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV</em><em>®</em><em> study presented today at ASGCT 2026 Annual Meeting along with initial rese-cel translational data using Cellares’ industrialized, automated manufacturing</em></p> <p align="center"><em>PC-free rese-cel initial data from the lowest dose RESET-SLE™ cohort expected in 1H26</em></p> <p align="center"><em>Pivotal RESET-Myositis</em><em>®</em><em> cohort with outpatient dosing option progressing to support first planned BLA submission for rese-cel next year</em></p> <p align="center"><em>Second pivotal indication for advancement to be announced after presentation of complete Phase 1/2 lupus and scleroderma data during June 2026 EULAR Congress</em></p> <p>PHILADELPHIA, http://www.streetinsider.com/Globe+Newswire/Cabaletta+Bio+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26489765.html Thu, 14 May 2026 07:05:00 -0400 A.50200932 A.50214086 A.60012014 CABA O.05000176 O.29757805 O.41847823 O.42045967 http://www.streetinsider.com/Globe+Newswire/Cabaletta+Bio+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26489765.html <p align="center"><em>Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV</em><em>®</em><em> study presented today at ASGCT 2026 Annual Meeting along with initial rese-cel translational data using Cellares’ industrialized, automated manufacturing</em></p> <p align="center"><em>PC-free rese-cel initial data from the lowest dose RESET-SLE™ cohort expected in 1H26</em></p> <p align="center"><em>Pivotal RESET-Myositis</em><em>®</em><em> cohort with outpatient dosing option progressing to support first planned BLA submission for rese-cel next year</em></p> <p align="center"><em>Second pivotal indication for advancement to be announced after presentation of complete Phase 1/2 lupus and scleroderma data during June 2026 EULAR Congress</em></p> <p>PHILADELPHIA, http://www.streetinsider.com/Globe+Newswire/Cabaletta+Bio+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26489765.html Thu, 14 May 2026 07:05:00 -0400 A.50200932 A.50214086 A.60012014 CABA O.05000176 O.29757805 O.41847823 O.42045967 http://www.streetinsider.com/Globe+Newswire/Cabaletta+Bio+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26489765.html <p align="center"><em>Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV</em><em>®</em><em> study presented today at ASGCT 2026 Annual Meeting along with initial rese-cel translational data using Cellares’ industrialized, automated manufacturing</em></p> <p align="center"><em>PC-free rese-cel initial data from the lowest dose RESET-SLE™ cohort expected in 1H26</em></p> <p align="center"><em>Pivotal RESET-Myositis</em><em>®</em><em> cohort with outpatient dosing option progressing to support first planned BLA submission for rese-cel next year</em></p> <p align="center"><em>Second pivotal indication for advancement to be announced after presentation of complete Phase 1/2 lupus and scleroderma data during June 2026 EULAR Congress</em></p> <p>PHILADELPHIA, http://www.streetinsider.com/Globe+Newswire/Cabaletta+Bio+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26489765.html Thu, 14 May 2026 07:05:00 -0400 A.50200932 A.50214086 A.60012014 CABA O.05000176 O.29757805 O.41847823 O.42045967 http://www.streetinsider.com/Globe+Newswire/Cabaletta+Bio+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26489765.html <p align="center"><em>Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV</em><em>®</em><em> study presented today at ASGCT 2026 Annual Meeting along with initial rese-cel translational data using Cellares’ industrialized, automated manufacturing</em></p> <p align="center"><em>PC-free rese-cel initial data from the lowest dose RESET-SLE™ cohort expected in 1H26</em></p> <p align="center"><em>Pivotal RESET-Myositis</em><em>®</em><em> cohort with outpatient dosing option progressing to support first planned BLA submission for rese-cel next year</em></p> <p align="center"><em>Second pivotal indication for advancement to be announced after presentation of complete Phase 1/2 lupus and scleroderma data during June 2026 EULAR Congress</em></p> <p>PHILADELPHIA, http://www.streetinsider.com/Globe+Newswire/Cabaletta+Bio+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26489765.html Thu, 14 May 2026 07:05:00 -0400 A.50200932 A.50214086 A.60012014 CABA O.05000176 O.29757805 O.41847823 O.42045967 http://www.streetinsider.com/Globe+Newswire/Cabaletta+Bio+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26489765.html <p align="center"><em>Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV</em><em>®</em><em> study presented today at ASGCT 2026 Annual Meeting along with initial rese-cel translational data using Cellares’ industrialized, automated manufacturing</em></p> <p align="center"><em>PC-free rese-cel initial data from the lowest dose RESET-SLE™ cohort expected in 1H26</em></p> <p align="center"><em>Pivotal RESET-Myositis</em><em>®</em><em> cohort with outpatient dosing option progressing to support first planned BLA submission for rese-cel next year</em></p> <p align="center"><em>Second pivotal indication for advancement to be announced after presentation of complete Phase 1/2 lupus and scleroderma data during June 2026 EULAR Congress</em></p> <p>PHILADELPHIA, http://www.streetinsider.com/Globe+Newswire/Cabaletta+Bio+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26489765.html Thu, 14 May 2026 07:05:00 -0400 A.50200932 A.50214086 A.60012014 CABA O.05000176 O.29757805 O.41847823 O.42045967